Healthcare
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition. White matter myelin integrity demonstrated a statistically significant treatment difference at Week 24 in the modified intent-to-treat population (p < 0.01), with larger effects observed in patients selected using the company’s biomarker enrichment strategy. BOCA RATON, Fla., July 09, 2026 (GLOBE NE
About this update from Inmune Bio Inc.
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition. White matter myelin integrity demonstrated a statistically significant treatment difference at Week 24 in the modified intent-to-treat population (p < 0.01), with larger effects observed in patients selected using the company's biomarker enrichment strategy. BOCA RATON, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced new imaging data from its Phase 2 study of XPro in patients with early Alzheimer's disease (AD). The data, to be presented at the Alzheimer's Association International Conference (AAIC), support early, concordant treatment-related effects across independent white matter and gray matter imaging endpoints. The presentation, titled "Concordant White Matter and Cortical Treatment Effects in a Phase 2 Study of XPro1595 in Early Alzheimer's disease," highlights the full chi-separation analysis of white matter myelin, together with cortical disarray measurement (CDM), an advanced diffusion-MRI measure of gray matter microstructure. The two techniques rely on different MRI contrast mechanisms: chi-separation uses magnetic susceptibility, while CDM uses water diffusion. They also use separate acquisition sequences and processing pipelines and, in this study, were applied to different tissue compartments. Because these methodologically independent measures changed in the same direction, their concordance supports the interpretation that the observed changes are treatment-related and reflect effects on brain microstructure. "Microstructural integrity in gray and white matter represents an important set of biomarkers in Alzheimer's disease because these changes reflect early pathological processes that contribute to cognitive decline," stated Dr. CJ Barnum, Vice President of Neuroscience at INmune Bio. "Detecting a treatment effect on white matter myelin within just 24 weeks, corroborated by cortical gray matter changes measured using an independent imaging method, supports the conclusion that XPro™ is engaging relevant biology earlier than traditional volumetric approaches would be expected to reveal." The upcoming AAIC presentation builds d...